Waldenstrom's Macroglobulinemia
Waldenstrom's Macroglobulinemia Clinical Trials

Waldenstrom's Macroglobulinemia Clinical Trials

Diseases such as waldenstrom's macroglobulinemia are at a disadvantage with regards to clinical trials because of the rarity of the disease. Such diseases are referred to as 'orphan' diseases and do not often get much funding for research and clinical trials. Clinical trials have the goal of finding better ways to prevent or treat a disease by using human volunteers and testing new treatments. Clinical trials are extremely important for waldenstrom's macroglobulinemia treatment because a cure or more effective treatment still needs to be found. Many effective disease treatments today have come from clinical trials which can also be used to refine methods of treatment such as perfecting dosages. Trials have also studied in more details waldenstrom's macroglobulinemia symptoms & diagnosis.

Waldenstrom's Macroglobulinemia Trials

Because the treatment options for waldenstrom's macroglobulinemia are still fairly limited and unknown, patients may want to get involved in clinical trials. This is obviously a personal decision and one that should be consulted upon with your doctor who can advise ways to get into trials. One thing to consider is that clinical trials provide first rate care and often provide better results on average, particularly in rare diseases like waldenstrom's macroglobulinemia. The costs of clinical trials are paid for by the trial sponsor so this is also a positive for patients who are able to get a place on a trial. A good resource for finding out about waldenstrom's macroglobulinemia clinical trials are; The International Waldenstrom's Macroglobulinemia Foundation.